Earnings summaries and quarterly performance for BAXTER INTERNATIONAL.
Executive leadership at BAXTER INTERNATIONAL.
Board of directors at BAXTER INTERNATIONAL.
Amy Wendell
Detailed
Director
Brent Shafer
Detailed
Chair of the Board
Cathy Smith
Detailed
Director
David Wilkes
Detailed
Director
Jeffrey Craig
Detailed
Director
Nancy Schlichting
Detailed
Lead Independent Director
Patricia Morrison
Detailed
Director
Stephen Oesterle
Detailed
Director
Stephen Rusckowski
Detailed
Director
William Ampofo
Detailed
Director
Research analysts who have asked questions during BAXTER INTERNATIONAL earnings calls.
Travis Steed
Bank of America
7 questions for BAX
Also covers: ABT, AXNX, BBNX +19 more
Vijay Kumar
Evercore ISI
7 questions for BAX
Also covers: A, ABT, AVTR +21 more
David Roman
Goldman Sachs Group Inc.
6 questions for BAX
Also covers: ABT, BDX, BLCO +18 more
Larry Biegelsen
Wells Fargo & Company
5 questions for BAX
Also covers: ABT, ALC, AXNX +24 more
Joanne Wuensch
Citigroup Inc.
4 questions for BAX
Also covers: ABT, BDX, BLCO +18 more
Robert Marcus
JPMorgan Chase & Co.
4 questions for BAX
Also covers: ABT, BDX, BLCO +21 more
Danielle Antalffy
UBS Group AG
2 questions for BAX
Also covers: ABT, ATRC, BSX +15 more
Lawrence Biegelsen
Wells Fargo
2 questions for BAX
Also covers: ABT, ALC, BDX +16 more
Matt Miksic
Barclays Investment Bank
2 questions for BAX
Also covers: ABT, ATEC, BLCO +14 more
Matt Mixkit
Barclays PLC
2 questions for BAX
Matt Taylor
Jefferies & Company Inc.
2 questions for BAX
Also covers: BIO, DXCM, ESTA +10 more
Pito Chickering
Deutsche Bank
2 questions for BAX
Also covers: ACHC, AHCO, AVAH +18 more
Robbie Marcus
JPMorgan Chase & Co.
2 questions for BAX
Also covers: ABT, BDX, BLCO +9 more
Matthew Miksic
Barclays PLC
1 question for BAX
Also covers: ABT, ATEC, BDX +15 more
Recent press releases and 8-K filings for BAX.
Baxter International shareholders urged to meet lawsuit filing deadline
BAX
Legal Proceedings
- Deadline: Investors who acquired BAX between Feb. 23, 2022 and July 30, 2025 must file a lead plaintiff motion by Dec. 15, 2025 to participate in the class action.
- Allegations: The lawsuit claims Baxter failed to disclose systemic defects in its Novum IQ Large Volume Pump, leading to underinfusion, overinfusion, 79 serious injuries and 2 patient deaths.
- Material event: On July 31, 2025, Baxter paused all Novum LVP shipments; its stock fell 22.4% ($6.24) to $21.61.
- Next steps: Affected shareholders may contact Glancy Prongay & Murray LLP to join the lawsuit or remain as absent class members.
3 days ago
Baxter announces early tender results for 2026 and 2027 senior notes
BAX
Debt Issuance
- As of the early tender cutoff on Dec. 3, 2025, valid tenders totaled $420.589 million of the $750 million 2.600% Senior Notes due 2026 and $1,088.66 million of the $1,450 million 1.915% Senior Notes due 2027.
- Baxter elected early settlement for accepted tenders on Dec. 8, 2025; $30 per $1,000 principal early tender payment included, with final Total Consideration to be set at 10:00 a.m. on Dec. 4, 2025.
- Tender offers for 2027 Notes will be accepted pro rata up to the $600 million maximum cap; no further tenders are expected to be accepted after the early date.
7 days ago
Baxter outlines operational focus and market challenges at Evercore HealthCONx
BAX
Guidance Update
Demand Weakening
Product Launch
- CFO Joel Grade says new CEO Andrew brings strong operational background and will emphasize continuous improvement, stabilizing key businesses and balance sheet deleveraging.
- Three main factors driving 2025 guidance downs: Novum pump disruptions, IV fluid conservation settling at 10–15% below pre-hurricane levels, and softness in US injectable pharmaceuticals.
- Demand for Spectrum pumps remains robust; total pump sales represent <2% of revenues with US market share in the high-20s, aided by common tube and set compatibility.
- Baxter is now enforcing GPO volume commitments post-allocation period, with pricing adjustments for unmet targets reflecting a new normal in fluid usage.
- CCS order book is up 30% year-to-date, frontline care markets have stabilized, and Baxter plans to launch the next-gen Connex 360 monitor in Q4 2025.
Dec 2, 2025, 3:50 PM
Baxter outlines operational focus, guidance drivers, and product pipeline at HealthCONx
BAX
CEO Change
Guidance Update
Product Launch
- CFO Joel Grade highlighted that new CEO Andrew brings a continuous improvement mindset to stabilize ITT and pharma businesses, focus on deleveraging, and drive predictable execution.
- Baxter attributed multiple 2025 guidance cuts to the Novum pump safety ship‐hold (~2% of sales), a new-normal 10–15% reduction in hospital fluid volumes post-hurricane, and softness in U.S. pharma injectables (lower Premix uptake).
- Demand for the legacy Spectrum pump remains strong, prompting a production ramp‐up as customers swap or return Novum units.
- The Connex 360 next‐generation patient monitor, featuring enhanced cybersecurity, launched in Q4 2025 and is expected to contribute to 2026 growth.
Dec 2, 2025, 3:50 PM
Baxter outlines fiscal 2025 guidance cut drivers and outlook at HealthCONx
BAX
Guidance Update
Demand Weakening
Management Change
- Baxter’s new CEO Andrew brings a “continuous improvement” operating mindset to stabilize ITT and pharma businesses and accelerate balance sheet deleveraging
- Fiscal Q4 guidance was cut due to uncertainties around Novum infusion pump issues, including under-infusion risks and potential returns, with pump sales under 2% of revenue; Spectrum pump demand remains solid ** **
- Baxter’s hospital fluid business has reached a “new normal” about 10–15% below pre-hurricane levels, prompting renewals of GPO volume commitments and potential pricing adjustments
- Pharmaceutical injectables, particularly Premix products, saw softness as some customers opted to buy vials and mix in-house, though Baxter deems this shift transitory and continues ROI education efforts
- Capital equipment orders rose 30% year-to-date, driven by strong CCS and HST performance, with improved order-to-revenue visibility supporting a stable frontline care outlook
Dec 2, 2025, 3:50 PM
Baxter International Faces Securities Litigation Investigation
BAX
Legal Proceedings
- Faruqi & Faruqi, LLP is investigating potential claims against Baxter International over alleged false or misleading statements about its Novum LVP infusion pumps.
- The complaint asserts these devices suffered systemic defects—underinfusion, overinfusion, and non-delivery—prompting Baxter to pause shipments on July 31, 2025, when its stock dropped 22.4% to $21.76.
- Investors who bought Baxter securities between February 23, 2022, and July 30, 2025, must move by December 15, 2025, to seek lead plaintiff status in the class action.
- Faruqi & Faruqi urges whistleblowers and others with relevant information to contact partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310).
Nov 29, 2025, 1:12 PM
Baxter International investors reminded of class action rights
BAX
Legal Proceedings
- Bragar Eagel & Squire has commenced a class action on behalf of Baxter investors concerning alleged defects in its Novum LVP infusion pumps, claiming systemic malfunctions and undisclosed safety risks.
- The case covers the period from February 23, 2022 to July 30, 2025, with a lead plaintiff deadline of December 15, 2025.
- Plaintiffs allege Baxter failed to disclose pump design flaws causing underinfusion, overinfusion, and non-delivery of fluids, which led to injuries and deaths, and misrepresented product safety and sales prospects.
Nov 28, 2025, 4:22 PM
Baxter International increases tender offer cap for 2027 notes
BAX
Debt Issuance
- Baxter International doubled the maximum purchase price for its cash tender offer on 1.915% Senior Unsecured Notes due 2027 from $300 million to $600 million.
- The tender offer for its 2.600% Senior Unsecured Notes due 2026 remains unchanged.
- The repurchases will be funded partly by proceeds from a concurrent offering of new senior unsecured notes, with excess proceeds used to repay its term loan credit facility and remaining 2026 Notes.
- Citi, BofA Securities, and JPMorgan Securities are acting as dealer managers, with D.F. King serving as tender and information agent, and offers are subject to a Financing Condition.
- Baxter reserves the right to further increase the tender cap for the 2027 Notes at its discretion, subject to applicable law.
Nov 19, 2025, 4:56 PM
Baxter outlines strategic update at Jefferies London Healthcare Conference 2025
BAX
Product Launch
- Completed key strategic divestitures (BPS and Vantive/kidney business) post-2021 Hillrom acquisition to reduce debt and refocus on core portfolio, with no further large sales planned but ongoing portfolio review.
- Provided segment outlook: MPT faces extended Novum pump recall (beyond 2025) but leans on Spectrum pump and 11% growth in advanced surgery; HST reports 30% increase in order book and stabilizing frontline care; Pharma sees rapid compounding growth, anesthesia recovery, and U.S. injectables softness from IV-push shifts.
- Targeting margin expansion and cash-flow improvement through new product launches (e.g., Connex 360 monitor), mix optimization, cost-leverage initiatives, and elimination of stranded costs by end-2027.
- Emphasizing connected-care strategy leveraging Hillrom tech (e.g., integrated nurse-call devices) to enhance device interoperability and patient monitoring, strengthening customer stickiness.
- Plans to host an analyst day in 2026 and to provide 2026 guidance on the Q4 earnings call.
Nov 18, 2025, 1:00 PM
Baxter outlines strategic stabilization and segment outlook at Jefferies conference
BAX
- After the Hillrom acquisition (Dec 2021) and subsequent sales of its BPS and kidney businesses in Jan 2023, Baxter’s CFO said no further large portfolio changes are planned; focus now is on operational consistency, cash generation, and reinvestment.
- In MPT, Spectrum pumps (1,500 U.S./Canada sites) will bridge demand while the Novum pump remains on voluntary recall (timeline extends beyond 2025); fluids reset to a new baseline post-hurricane; HST CCS orders are up 30%, and pharma growth is driven by compounding and anesthesia but U.S. injectables face mix headwinds.
- Pricing tailwinds include ~100 bp of price gains from two re-negotiated GPO contracts in 2025 (third contract renegotiation begins late 2026), while tariffs are a ~$40 m P&L and ~$110 m cash headwind being offset by targeted pricing and supply-chain actions; margin levers also include the Connex 360 monitor launch, manufacturing cost programs, and SG&A savings from kidney business divestiture by end 2027.
- Baxter plans an analyst day in 2026 for its long-range plan update and will provide 2026 guidance on its Q4 call; management will continuously evaluate the portfolio under the new CEO but sees no material changes.
Nov 18, 2025, 1:00 PM
Quarterly earnings call transcripts for BAXTER INTERNATIONAL.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more